Expression of Golgi membrane protein p138 is cell cycle-independent and dissociated from centrosome duplication.
In order to elucidate the mechanism controlling the biogenesis of the Golgi complex, we have studied whether the expression of a resident membrane protein p138 of the Golgi complex is dependent upon the cell cycle. The protein level of p138 in human KB cells was increased during thymidine block to synchronize the cells in the early-S phase, but changed little from S to G2 after release from the block. On the other hand, the mRNA level of the p138 gene was constant during the block. The change in mRNA level in the cells was small with a low peak at S to G2. Both p138 protein and mRNA levels decreased after cell division and then rose rapidly to the same level as those of log-phase cells in the next G1 to S. Thus, translation of p138 protein was upregulated in the cells at the early-S phase. However, we found also that the p138 protein level increased during an arrest at G2/M caused by etoposide. The kinetics of centrosome duplication apparently differ from those of p138 protein production. The duplication occurred mainly at S to G2 after the release from thymidine block, while the ratio of cells containing duplicated centrosomes increased gradually during the block. Taken together, these results show that both the translation and transcription of p138 protein are regulated independent of the cell cycle and dissociated from the duplication of the centrosome. Rather, the expression of p138 protein seems to be coupled with a change in cell size since both thymidine block and etoposide inhibition resulted in an apparent increase in cell size.
Department of Life Science, Faculty of Science and Technology, Kwansei Gakuin University, Hyogo-ken, Japan.
Kohei
K
Doi
Shohei
S
Noma
Fumiaki
F
Yamao
Hideki
H
Goko
Tatsuo
T
Yagura
D002453:Cell Cycle; D048429:Cell Size / Q000187:drug effects; D018385:Centrosome / Q000502:physiology*; D005047:Etoposide / Q000494:pharmacology; D005434:Flow Cytometry; D016195:G2 Phase / Q000502:physiology; D006056:Golgi Apparatus / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006825:Hybridomas; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism*; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D008938:Mitosis / Q000502:physiology; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D016196:S Phase / Q000502:physiology; D013936:Thymidine / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors; D033921:Vesicular Transport Proteins
C107340:GOLIM4 protein, human; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D019384:Nucleic Acid Synthesis Inhibitors; D010750:Phosphoproteins; D012333:RNA, Messenger; D059005:Topoisomerase II Inhibitors; D033921:Vesicular Transport Proteins; D005047:Etoposide; D013936:Thymidine